Boceprevir - Wikipedia
网页Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. [ 2 ] [ 3 ] It binds to the HCV nonstructural protein 3 active site.
Victrelis: Uses, Dosage, Side Effects & Warnings - Drugs.com
网页2023年8月23日 · Victrelis (boceprevir) is an antiviral medication used in combination with other medicines to treat chronic hepatitis C. Includes Victrelis side effects, interactions and indications.
Boceprevir (Oral Route) Proper Use - Mayo Clinic
网页For oral dosage form (capsules): For hepatitis C virus infection, in combination with peginterferon alfa and ribavirin: Adults—800 milligrams (mg) (four 200-mg capsules) 3 times a day with food. Each dose should be taken 7 to 9 hours apart. Children—Use and dose must be determined by your doctor.
Boceprevir: Uses, Interactions, Mechanism of Action - DrugBank …
网页Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Boceprevir (Oral Route) Description and Brand Names - Mayo Clinic
网页Boceprevir is used in combination with injectable peginterferon alfa (Pegasys®, Pegintron®) and ribavirin (Copegus®, Rebetol®) to treat chronic hepatitis C infection.
Boceprevir: MedlinePlus Drug Information
网页Boceprevir is in a class of medications called protease inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Boceprevir may not prevent the spread of hepatitis C to other people.
Boceprevir Advanced Patient Information - Drugs.com
网页2023年11月18日 · Boceprevir is a direct-acting antiviral agent that treats hepatitis C infection. This medicine is available only with your doctor's prescription. Before using boceprevir
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
网页2011年3月31日 · Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies. Methods. We conducted a double-blind study in which...
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
网页2011年3月31日 · Boceprevir is a structurally novel peptidomimetic ketoamide protease inhibitor that binds reversibly to the HCV nonstructural 3 (NS3) active site. 8 Boceprevir has demonstrated antiviral...
The Discovery and Development of Boceprevir: A Novel, First …
网页2013年9月15日 · The boceprevir phase III clinical program consisted of two international randomized trials in patients with HCV genotype 1 infection. Previously untreated patients were enrolled in SPRINT2 (n = 1097) and treatment-experienced patients were enrolled in RESPOND2 (n = 403).
- 某些结果已被删除